Analysts Offer Insights on Healthcare Companies: Neumora Therapeutics, Inc. (NMRA), Medline, Inc. Class A (MDLN) and Tecan Group AG (OtherTCHBF)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Neumora Therapeutics, Inc. (NMRA – Research Report), Medline, Inc. Class A (MDLN – Research Report) and Tecan Group AG (TCHBF – Research Report) with bullish sentiments.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Medline, Inc. Class A (MDLN)
UBS analyst Kevin Caliendo initiated coverage with a Buy rating on Medline, Inc. Class A today and set a price target of $48.00. The company’s shares closed last Friday at $40.52.
According to TipRanks.com, Caliendo is a 4-star analyst with an average return of
Currently, the analyst consensus on Medline, Inc. Class A is a Strong Buy with an average price target of $48.42, implying a 16.7% upside from current levels. In a report released yesterday, Morgan Stanley also initiated coverage with a Buy rating on the stock with a $48.00 price target.
Tecan Group AG (TCHBF)
In a report issued on January 9, Harry Gillis from Berenberg Bank maintained a Buy rating on Tecan Group AG, with a price target of CHF205.00. The company’s shares closed last Friday at $159.55.
According to TipRanks.com, Gillis is a 3-star analyst with an average return of
Currently, the analyst consensus on Tecan Group AG is a Hold with an average price target of $209.88.
